每经AI快讯，港股医药股普遍下挫。截至发稿，歌礼制药-B(01672.HK)跌11.02%，报12.92港元；圣诺 医药-B(02257.HK)跌8.27%，报8.32港元；和铂医药-B(02142.HK)跌7.29%，报12.46港元；荣昌生物 (09995.HK)跌4.87%，报75.15港元。 ...

智通财经APP获悉，医药股普遍下挫，截至发稿，歌礼制药-B(01672)跌11.02%，报12.92港元；圣诺医 药-B(02257)跌8.27%，报8.32港元；和铂医药-B(02142)跌7.29%，报12.46港元；荣昌生物(09995)跌 4.87%，报75.15港元。 消息面上，海通国际研报指出，医药板块回调，资金面短期承压；看好创新药产业链长期机会。上周港 股医药板块整体表现较弱，该行认为主要受南下资金年底结账等季节性因素影响，港股医药板块流动性 减弱，医药龙头股的港股通持股比例持续下滑，例如信达生物、中国生物制药等。该行长期看好业绩确 定性强的互联网医疗、CXO/科研服务龙头，以及已经实现对外合作授权、海外临床进展顺利、基本面 强劲的头部Biotech和制药公司。 ...

Core Viewpoint - The pharmaceutical sector is experiencing a general decline, with significant drops in stock prices for various companies, attributed to seasonal factors affecting liquidity and southbound fund flows [1] Group 1: Market Performance - Major pharmaceutical stocks have seen substantial declines, with Gilead Sciences-B (01672) down 11.02% to HKD 12.92, Sanofi-B (02257) down 8.27% to HKD 8.32, and Hengrui Medicine-B (02142) down 7.29% to HKD 12.46 [1] - Overall, the Hong Kong pharmaceutical sector has performed weakly, influenced by seasonal factors such as year-end fund settlement [1] Group 2: Analyst Insights - Haitong International's report indicates that the pharmaceutical sector is under short-term pressure due to liquidity issues, but maintains a positive long-term outlook on the innovative drug industry chain [1] - The report highlights a continuous decline in the Hong Kong Stock Connect holdings of leading pharmaceutical stocks, such as Innovent Biologics and China National Pharmaceutical Group [1] Group 3: Long-term Opportunities - The firm expresses confidence in the long-term prospects of internet healthcare, CXO/research service leaders, and top biotech and pharmaceutical companies that have established external collaborations and are making progress in overseas clinical trials [1]

港股生物技术板块持续走低，歌礼制药(01672.HK)跌超8%，圣诺医药(02257.HK)跌超6%，百济神州 (06160.HK)、复宏汉霖(02696.HK)等跟跌。 本文源自：金融界AI电报 ...

香港联交所最新资料显示，12月8日，董事会主席潘洪辉增持圣诺医药(02257)10万股，每股作价6.83港 元，总金额为68.3万港元。增持后最新持股数目约为1762.77万股，最新持股比例为16.44%。 ...

智通财经APP获悉，香港联交所最新资料显示，12月8日，董事会主席潘洪辉增持圣诺医药(02257)10万 股，每股作价 6.83港元，总金额为68.3万港元。增持后最新持股数目约为1762.77万股，最新持股比例为 16.44%。 ...

据潘洪辉告知，彼对集团整体发展前景及潜在增长充满信心。在符合适用法律及监管规定情况下，潘洪 辉不排除彼可能会于适当时进一步增持公司股份。 格隆汇12月8日丨圣诺医药-B(02257.HK)公告，公司董事会获公司执行董事兼主席潘洪辉告知，潘洪辉 已于2025年12月8日以其个人资金于公开市场按每股股份约6.83港元的平均价格购入合共10万股公司普 通股，总代价约为68.3万港元。紧随购入后，潘于合共17,627,696股股份中拥有权益，占公司于本公告 日期已发行股本总额16.44%。 ...

Core Viewpoint - The company announced that its Executive Director and Chairman, Dr. Pan Honghui, purchased 100,000 shares at an average price of approximately HKD 6.83 per share, totaling around HKD 683,000, indicating confidence in the company's growth prospects [1] Group 1: Share Purchase Details - Dr. Pan acquired 100,000 ordinary shares in the open market at an average price of approximately HKD 6.83 per share [1] - The total cost of the share purchase was approximately HKD 683,000 [1] - Following the purchase, Dr. Pan holds a total of 17,627,696 shares, representing 16.44% of the company's issued share capital as of the announcement date [1] Group 2: Future Intentions - Dr. Pan expressed confidence in the overall development prospects and potential growth of the group [1] - He does not rule out the possibility of further increasing his shareholding in the company at an appropriate time, subject to applicable laws and regulations [1]

Core Viewpoint - Dr. Pan Honghui, the Executive Director and Chairman of Sanofi Pharmaceutical-B (02257), has purchased 100,000 shares of the company at an average price of approximately HKD 6.83 per share, totaling around HKD 683,000, indicating confidence in the company's growth prospects [1] Summary by Relevant Sections - **Share Purchase Details** - Dr. Pan acquired 100,000 shares at an average price of HKD 6.83 per share, amounting to HKD 683,000 [1] - Following the purchase, Dr. Pan holds a total of 17,627,696 shares, representing 16.44% of the company's issued share capital as of the announcement date [1] - **Outlook and Future Intentions** - Dr. Pan expressed strong confidence in the overall development prospects and potential growth of the group [1] - He does not rule out the possibility of further increasing his shareholding in the company at an appropriate time, in compliance with applicable laws and regulations [1]

香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部份 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 本公司董事會（「董事會」）獲本公司執行董事兼主席潘洪輝博士（「潘博士」） 告 知 ， 潘 博 士 已 於 2025 年 12 月 8 日 以 其 個 人 資 金 於 公 開 市 場 按 每 股 股 份 約 6.83 港 元 的 平 均 價 格 購 入 合 共 100,000 股 本 公 司 普 通 股（「股 份」）， 總 代 價 約 為683,000港元。緊隨購入後，潘博士於合共17,627,696股股份中擁有權益， 佔本公司於本公告日期已發行股本總額之16.44%。 據 潘 博士 告 知 ， 彼 對本 集 團 之 整體 發 展 前 景 及潛 在 增 長 充 滿信 心 。 在 符合 適 用 法律 及 監 管 規 定之 情 況 下 ，潘 博 士 不 排 除 ...